British Columbia's Health Ministry is limiting the sales of two more diabetes drugs to curb their off-label use for weight ...

In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is ...

Finland is demonstrating a different approach to modern healthcare—one that prioritizes accessibility, respect, and ...

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release ...

In 2025, the discourse surrounding prescription weight loss treatments is gaining momentum, fueled by increasing public awareness of GLP-1 receptor agonists, such as semaglutide and tirzepatide ...

The resolution of shortages for tirzepatide and other GLP-1 medications, such as semaglutide, signals a potential shift toward increased FDA enforcement as the agency works to align industry ...

New research compared the effect of semaglutide vs. tirzepatide on weight loss over a 72 week period. Here's what the study found, and what a doctor has to say about it.

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference. And ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, according to findings from the SURMOUNT-5 trial.